Day: July 6, 2021

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience.

Mr. Fekete is an advisor and board member for companies in the pharmaceutical, biotechnology and medical device industries. His areas of expertise include business strategy, capital markets, M&A and corporate governance developed through 35 years as an investment banker, independent advisor and board member for U.S. and international public and private companies. He currently serves as a member for SeaSpine, Inc. (NASDAQ: SPNE), a California based medical technology company focused on surgical solutions for the treatment of spinal disorders, and DFB Pharmaceuticals, a Texas based, private investment and development company focused on the formation and building of businesses in the pharmaceutical industry. He previously worked as an investment banker for Wells Fargo/Wachovia Securities, CIBC World Markets, Oppenheimer & Co., and L.F. Rothschild, Unterberg, Towbin. He obtained his B.S. in Finance from The Pennsylvania State University.

Mr. Greg Tibbitts is a Certified Public Accountant and has over 30 years of experience as a financial executive and a public accountant. His expertise includes addressing technical accounting issues, multiple public and private equity financings, complex operations, and direct interactions with the SEC on IPO and secondary offerings. He has worked as a Chief Financial Officer for both public and private companies and now operates a business advisory firm. He served as a board member for IDMI Pharma, Inc., a NASDAQ listed biotech company prior to its acquisition. He obtained a B.B.A. in Accounting at University of San Diego and a M.B.A. at San Diego State University.

“We are excited to welcome Mike and Greg to the CoImmune board,” stated Dr. Charles Nicolette, chief executive officer and member of the board of directors. “These gentlemen bring considerable biotechnology industry and strategic expertise that will benefit CoImmune as we seek to advance our novel pipeline of cell-based immunotherapies directed at important diseases, including acute lymphoblastic leukemia and advanced renal cell carcinoma.”

About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.

For more information, visit www.coimmune.com.

Contact:
Lori Harrelson
Chief Financial Officer
lharrelson@coimmune.com
919-287-6349

58 Clinical Trial Sites, 11 Countries

EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided encouraging results and supported continuation of the study.

Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting. Enrolment of 221 patients was completed three months ahead of schedule. The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.

“To have patient enrolment completed three months ahead of schedule, despite the global pandemic, reinforces the strength of commitment of TRIO’s investigator network,” stated Dr. Vanesa Quiroga, a member of the trial’s Steering Committee, GEICAM and Catalan Institute of Oncology. “The scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.”

More information on the coopERA Breast Cancer trial (WO42133/TRIO038/coopERA) can be found at clinicaltrials.gov (NCT04436744).

About TRIO
TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO’s global reach is expansive. Our goal as an academic clinical research organization is to find the shortest path to saving lives. Additional information on TRIO can be found by visiting https://www.trioncology.org. Interested parties may also follow TRIO on Twitter (twitter.com/TRIOncology).

TRIO Media Inquiries:
Launa Aspeslet, PhD
CEO, TRIO
Email: launa.aspeslet@trioncology.org
Phone: 780-702-2260

Multi-year Agreement for Mobile Automatic Number Plate Recognition (ANPR) Solutions Support Road Safety and More Efficient Customs and Border Enforcement

Mobile ANPR Solution for Norwegian Public Roads Administration

Multi-year Agreement for Mobile Automatic Number Plate Recognition (ANPR) Solutions Support Road Safety and More Efficient Customs and Border Enforcement in Norway

SAN DIEGO, July 05, 2021 (GLOBE NEWSWIRE) — Neology, Inc., a global innovator that is re-imagining mobility for smart cities and safer communities, today announced an expanded, multi-year agreement with Norwegian Public Roads Administration (NPRA) for its traffic enforcement solutions driven by the latest in mobile ANPR camera and artificial intelligence (AI) technology to support real-time analytics and decision making.

Safeguarding the national road network and enabling border security agencies and their officers the capability to make accurate, informed decisions while keeping travel and trade flowing is the ultimate goal for NPRA. Neology’s ANPR safer community solutions provide enhanced performance, creating immediate impact where other solutions fail. The dual camera system, coupled with advanced AI-powered vehicle recognition technology, enables officers to detect and focus on non-compliant vehicles with enhanced vision system capabilities.

“We are thrilled that NPRA has expanded its partnership with Neology to meet its mobile ANPR requirements. Against a strong set of competitors, our solutions demonstrated both superior value and strong quality, plus our leading AI-based solutions outperformed our competitors in real-world testing during the tender evaluation stage,” said Luke Normington, General Manager of Neology. “When demands on transport authorities and law enforcement agencies are increasing, our innovative solutions help create safer, cleaner, more efficient mobility experiences that support sustainable growth and help communities thrive.”

About Neology, Inc.
Neology is re-imagining mobility to help our customers accelerate their vision for smart cities and safer communities. Our Mobility Platform™ is setting the industry standard through a unique combination of AI-powered adaptive solutions, a proven integration process, and unparalleled lifecycle support. Backed by a culture of innovation, our mobility experts work closely with global customers and a top-tier partner ecosystem to connect existing infrastructure assets with next-generation technology to modernize the way people move. To create safer, cleaner, more efficient mobility experiences, visit www.neology.net.

About NPRA
The Norwegian Public Roads Administration (NPRA) intends to lead the way in the development of an efficient, safe, comprehensive and coherent transport system adapted to tomorrow’s needs and technology. Our responsibility for national and European roads, as well as for road users and vehicles makes the NPRA the most prominent participant in the road transport sector in Norway. Accounting for two thirds of all traffic, our national and European roads make up the main transport system artery tying our country together. The NPRA is responsible for planning, building, operating and maintaining this part of the road network. We have national responsibility for emergency preparedness on the road as well as developing clear rules and standard specifications for smart transport and modern road construction for all roads. Through our work to supervise and inspect road users and vehicles, new technology and development of digital services, we will ensure that road users, businesses and industries have simple, efficient, safe and environmentally friendly transport options.

Neology Media Contact:
Kelly Foster
kelly@johnkellyfoster.com
+1 619-224-1261

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/78e279e1-6140-400f-859d-eac3d9b5c683